Scarica l'app Stockscreener
6.93
3.82%
0.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.68
Aprire:
$6.75
Volume 24 ore:
25,000
Relative Volume:
0.06
Capitalizzazione di mercato:
$391.09M
Reddito:
-
Utile/perdita netta:
$-72.89M
Rapporto P/E:
-2.8636
EPS:
-2.42
Flusso di cassa netto:
$-68.47M
1 W Prestazione:
-1.21%
1M Prestazione:
+8.87%
6M Prestazione:
-0.79%
1 anno Prestazione:
-28.94%
Intervallo 1D:
$6.69
$7.02
Intervallo di 1 settimana:
$6.06
$7.18
Portata 52W:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Nome
Astria Therapeutics Inc
Settore
Industria
Telefono
617-349-1971
Indirizzo
22 BOSTON WHARF ROAD, BOSTON
Confronta ATXS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
6.93 | 354.41M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.67 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.06 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.42 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.88 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.45 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-29 | Iniziato | TD Cowen | Buy |
| 2023-03-28 | Iniziato | Evercore ISI | Outperform |
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
Is it time to cut losses on Astria Therapeutics Inc.Pre-Market Stock Movement Summary and Review - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionEntry Optimization Tool with Screener Logic - Newser
Astria Therapeutics Inc. stock momentum explainedDay Trading Plan with Entry Risk Management - Newser
What earnings revisions data tells us about Astria Therapeutics Inc.Weekly Chart Watchlist with Trade Guidance - Newser
Can Astria Therapeutics Inc. hit a new high this monthTrend Confirmation Scanner with Entry Focus - Newser
How high can Astria Therapeutics Inc. stock goInvestment Life Cycle Planning Summary - Newser
Price action breakdown for Astria Therapeutics Inc.Free Portfolio Diversification Stock Ideas - Newser
How to build a dashboard for Astria Therapeutics Inc. stockWeekly Market Direction and Sector Summary - Newser
Can trapped investors hope for a rebound in Astria Therapeutics Inc.Historical Volatility and Pattern Breakdown Analysis - Newser
Will Astria Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsFree Market Momentum and Signal Alerts - Newser
How Astria Therapeutics Inc. stock performs during market volatilityFree Momentum Based Equity Trading Plan - Newser
Is Astria Therapeutics Inc. showing signs of accumulationInvestment Roadmap for High Potential Stocks - Newser
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
Astria Therapeutics Inc. stock prediction for this weekFree Smart Allocation Stock Pick Insights - Newser
Astria licenses rare disease drug Navenibart to Japan’s Kaken Pharma in $32 M deal - BioSpectrum Asia
Astria Therapeutics shares fall 1.15% intraday after being dropped from multiple Russell indices. - AInvest
Astria Therapeutics licenses navenibart rights to Kaken for HAE - Yahoo Finance
How to escape a deep drawdown in Astria Therapeutics Inc.Chart Confirmation Setup with ROI Signals - Newser
Astria Therapeutics’ Strategic Advancements and Market Potential: A Buy Recommendation by Joseph Pantginis - TipRanks
Astria Therapeutics: Strategic Partnership and Promising Phase 3 Trial Justify Buy Rating - TipRanks
Astria Therapeutics Strikes Licensing Deal in Japan - MarketScreener
Astria Therapeutics Licenses Japan Rights to Navenibart in $16mln Deal, Kaken Pharmaceutical to Support Phase 3 Trials and Commercialization - AInvest
Astria Therapeutics Licenses Japan Rights To Navenibart In $16 Mln Deal - Nasdaq
Astria Therapeutics Enters Licensing Deal with Kaken - TipRanks
Astria, Kaken ink deal to develop navenibart for HAE in Japan - MarketScreener
ATXS inks $16M navenibart deal with Kaken; runway now into 2028 | ATXS SEC FilingForm 8-K - Stock Titan
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan - Business Wire
Astria Therapeutics Grants Stock Options to Two New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
What catalysts could drive Astria Therapeutics Inc. stock higher in 2025Achieve impressive returns with smart timing - Jammu Links News
Applying sector rotation models to Astria Therapeutics Inc.Low Risk Stock Selection Strategy Guide - Newser
What is Astria Therapeutics Inc. company’s growth strategyMarket-beating performance - Jammu Links News
What institutional investors are buying Astria Therapeutics Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
Astria Therapeutics Inc Azioni (ATXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):